Just how independent is Genentech?
Questions continue to swirl as the unit mulls another oncology makeover.
TIGIT blows up in a trial that always looked risky
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
BioNTech claims a FixVac win
But the company hasn’t given details, and used a historical control rather than the study’s own control arm.
Roche’s Skyscraper looks on shaky foundations
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
Novartis drops out of KRAS
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
